Patients at the Myeloma Center have access to the newest therapies for plasma cell disorders through enrollment onto clinical trials. New clinical trials are now under continuing enrollment under the care of your treating physician. The myeloma center has access to both pharmaceutical industry and physician investigator initiated clinical trials as part of a world-class clinical research program.
In addition to clinical research, Weill Cornell Medical College has an active basic science laboratory-based research program in myeloma where new targets for drug therapy and disease control can be discovered. Innovations in the laboratory can then be used in an active bench-to-clinic translational research context, this offering patients in need the latest in personalized drug therapies.
Myeloma is a cancer of a type of white blood cell called the plasma cell. It is the job of the plasma cell to produce immunoglobulins, proteins which serve in an integral role in immune system protection. An abnormal proliferation of one type (or clone) or plasma cell can lead to a spectrum of blood disorders including MGUS (monoclonal gammopathy of undetermined significance), multiple myeloma, amyloidosis, light chain deposition disease, amongst others.
The Myeloma Center finishes move to new building
The Myeloma Center has successfully transitioned to the 428 E 72nd street practice in the Oxford building. In this practice, you will have consultations with your physician and undergo treatment in a comfortable and personal clinic setting. All myeloma-related procedures are done on site by the physicians as well for convenience.
Myeloma Center Awarded Prestigious LLS Translational Research Grant
The Myeloma Center in collaboration with Weill Cornell's Monical Guzman, PhD have received a prestigious translational research grant from the Leukemia and Lymphoma Society (LLS) to study the genesis of secondary malignancies in Multiple Myeloma.